Sharjah 24 – WAM: Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance and Coexistence, President of UAE Genetic Diseases Association, has honoured a number of leading healthcare companies and personalities at the Middle East’s first Precision Medicine Exhibition & Summit held at the Conrad Hotel, Dubai.

The event brought together thought leaders and medical pioneers from Asia, the Middle East, Europe, and the USA to unearth new opportunities in the digital technology-driven precision medicine (PM) field.

"I find the topic of this exhibition and summit fascinating. For years, I have been listening to the extraordinary promising future of several different emerging technologies. It is truly amazing to see the future began to turn into reality in precision medicine," said Sheikh Nahyan, adding that precision medicine will progress rapidly because the capacity to analyse huge volumes of data comes from the field of Big-Data, and the tools developed to implement it, are directly relevant to precision medicine and will accelerate its progress in unprecedent ways.

The event comes as the Middle East and Africa (MEA) region's precision medicine market is expected to grow by nearly 10 percent per year to US$2.1 billion in value within 18 months, transforming the region into a hub for the emerging sector.

Sheikh Nahyan presented awards at the inaugural PrecisionMed Exhibition and Summit, brought by the UAE Genetic Diseases Association, to companies and personalities who are changing the face of healthcare. Dr. Min S. Park, the Chief Scientific Officer of Sanimed International in Abu Dhabi, which makes culture medium, collagen, and advanced biotechnology products, was among the winners. Dr. Min was recognised for his mentorship, leadership, and contribution to the field of precision medicine.

Sharjah University was recognised for its achievement in topping the UAE’s 2020-2021 rankings in the publication of Advances in Biomedical and Health Sciences and its development of the implementation of single cell omics technique that furthers understanding of very high-resolution disease mechanisms to identify pathways and biomarkers.